A few clinical trials testing the efficacy of suppressing the EMT program are underway, and while Notch or HIF-1α inhibitors have been proposed to work by targeting stemness or the EMT, TGFβ inhibitors have been used to target tumor cells that have activated versions of the EMT program, and the WNT/FZD pathway is targeted for tumor dedifferentiation [127,141]. The gene discussed is TGFB1; the disease is neoplasm.